BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Feraheme ferumoxytol: Phase II data

The open-label, international Phase II FIRST trial in 162 patients with iron deficiency anemia and CKD showed that IV Feraheme produced comparable increases in hemoglobin from baseline to week 5 vs. IV iron sucrose. Additionally, a greater proportion of patients receiving Feraheme achieved a >=1 g/dL increase in hemoglobin vs. iron sucrose (50% vs. 42%). Furthermore, Feraheme-treated patients had a...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >